Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556275 | 0.93 | MAPK1 (0.47) | MAPK1DRD3POLBMEN1KMT2A | |
| SCHEMBL3557010 | 0.90 | CARM1 (0.52) | MAPK1DRD3POLBMEN1KMT2A | |
| SCHEMBL3566218 | 0.87 | CCR3 (0.58) | POLBMEN1KMT2APRMT6HTR1A | |
| SCHEMBL3557323 | 0.80 | CCR3 (0.60) | POLBMEN1KMT2AHTR1A | |
| SCHEMBL4853518 | 0.78 | UTS2R (0.67) | MAPK1DRD3MEN1KMT2ACARM1 | |
| SCHEMBL3556422 | 0.78 | KDM4E (0.40) | POLBMEN1KMT2AMAPT | |
| SCHEMBL3563441 | 0.77 | RAB9A (0.42) | POLBMEN1KMT2ADRD2DRD4 | |
| SCHEMBL27641304 | 0.77 | CCR3 (0.61) | MEN1KMT2A | |
| SCHEMBL3557299 | 0.77 | CCR3 (0.67) | POLBMEN1KMT2A | |
| SCHEMBL27661919 | 0.76 | CARM1 (0.56) | POLBMEN1KMT2ACARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | MAPK1 912/4885DRD3 235/4885POLB 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.